SAN DIEGO, Aug. 16, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) ( www.apricusbio.com) today announced a podium presentation titled, "Updated analyses of a randomized, double-blind, Phase 3 study of Femprox®, an alprostadil cream with a novel transdermal delivery technology (NexACT®) for the treatment of female sexual arousal disorder (FSAD)," will take place on Monday, August 27, 2012, at 4:30 p.m. CT, as part of the 2012 World Meeting on Sexual Medicine, which is being held August 26-30, 2012 in Chicago. The presentation will discuss an updated analysis of the approximately 400-women Phase III clinical trial conducted by Apricus Bio to provide further evidence of the statistically significant efficacy and safety profile of Apricus Bio's investigational drug, Femprox® (topical alprostadil 0.4 % cream), for the treatment of FSAD in pre- and post-menopausal women. The data will be presented by Dr. Irwin Goldstein, Director of Sexual Medicine at the Alvarado Hospital in San Diego, and a member of Apricus Bio's Femprox® Clinical Advisory Board. Dr. Goldstein is the Editor of The Journal of Sexual Medicine, a member of numerous sexual medicine societies, the author or co-author of approximately 260 peer-reviewed papers, and an expert in the area of women's sexual health. About Femprox ® Femprox® is an alprostadil-based 0.4% topical cream intended for the treatment of FSAD. Apricus Bio has completed nine clinical studies to date, including one, 98-patient Phase II study in the U.S. and a near 400-patient Phase III study in China. It is the Company's understanding that no product is currently approved in the U.S. for FSAD, a persistent or recurring inability to attain, or maintain adequate sexual excitement, causing personal distress. Femprox® exerts a local, relaxant effect on vulvar and clitoral blood vessels in women, leading to increased blood flow. The resultant increase in lubrication and sensory feedback is believed to produce a clinically significant increase in sexual arousal in women with FSAD.
About Apricus Biosciences, Inc.Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, high-demand therapeutic classes. The Company has four approved products and has developed a strong pipeline of multiple late-stage product opportunities. With commercial operations in both the U.S. and Europe (France), Apricus Bio generates revenues and growth from sales of its commercial products and by out-licensing, in certain territories, its pipeline products and NexACT® technology. Apricus Bio's growth strategy is to acquire, develop, and commercialize new products through strategic partnerships. The Company currently has commercial partnerships with multiple large pharmaceutical companies including Novartis, Abbot Laboratories, Sandoz, Warner Chilcott, Wockhardt, and Bracco, and co-promotes multiple products in France. Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on the NASDAQ under the ticker symbol APRI. For further information on Apricus Bio, visit http://www.apricusbio.com , and for information on its subsidiary please visit http://www.nexmedusa.com . You can also receive information at http://twitter.com/apricusbio . Apricus Bio's Forward-Looking Statement Safe Harbor Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to further develop its products and product candidates, to have its products and product candidates such as Femprox ® receive patent protection and be approved by relevant regulatory authorities, to successfully commercialize such products and product candidates as Femprox® and drug delivery technology and to achieve its development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
CONTACT: Apricus Bio Investor Relations: David Pitts Argot Partners 212-600-1902 email@example.com